Warts - Pipeline Review, H1 2018 - Product Image

Warts - Pipeline Review, H1 2018

  • ID: 4455922
  • Report
  • 91 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Aclaris Therapeutics Inc
  • Aviragen Therapeutics Inc
  • Cadila Healthcare Ltd
  • Cytovation AS
  • LEO Pharma A/S
  • Novan Inc
  • MORE
Warts - Pipeline Review, H1 2018

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Warts - Pipeline Review, H1 2018, provides an overview of the Warts (Infectious Disease) pipeline landscape.

Warts are skin growth that is caused by virus called human papillomavirus (HPV). HPV infects the top layer of skin, usually entering the body in an area of broken skin. The virus causes the top layer of skin to grow rapidly, forming a wart. Symptoms include pain and rough skin. Predisposing factors include age and people with weakened immune systems, such as those with HIV/AIDS or people who had organ transplants.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Warts - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Warts (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Warts (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Warts and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 16, 2, 5, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 2 molecules, respectively.

Warts (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Warts (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Warts (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Warts (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Warts (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Warts (Infectious Disease)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Warts (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Warts (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Aclaris Therapeutics Inc
  • Aviragen Therapeutics Inc
  • Cadila Healthcare Ltd
  • Cytovation AS
  • LEO Pharma A/S
  • Novan Inc
  • MORE
Introduction

Warts - Overview

Warts - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Warts - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Warts - Companies Involved in Therapeutics Development

Aclaris Therapeutics Inc

Agilvax Inc

Aviragen Therapeutics Inc

BioMAS Ltd

Cadila Healthcare Ltd

Cutanea Life Sciences Inc

Cytovation AS

G&E Herbal Biotechnology Co Ltd

Genetic Immunity Inc

Laboratories Ojer Pharma SL

LEO Pharma A/S

Nielsen Biosciences Inc

Novan Inc

Novartis AG

Promius Pharma LLC

RXi Pharmaceuticals Corp

Tamir Biotechnology Inc

Warts - Drug Profiles

(digoxin + furosemide) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

854-A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Albicin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AS-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AX-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Condyloma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CyPep-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DFD-05 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FIT-039 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

furosemide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

human papillomavirus [serotypes 6, 11] (bivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

human papillomavirus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

human papillomavirus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HupaDerm - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hydrogen peroxide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

imiquimod SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ingenol mebutate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

interferon alpha-2b - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LFX-453 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omiganan pentahydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

povidone iodine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PP-210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ranpirnase - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RKP-00156 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Samcyprone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SB-206 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRT-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

teslexivir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VP-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Warts - Dormant Projects

Warts - Discontinued Products

Warts - Product Development Milestones

Featured News & Press Releases

Jan 08, 2018: Aclaris Therapeutics A-101 45% Topical Solution Meets Primary and All Secondary Endpoints in Two Phase 2 Clinical Trials for Common Warts

Dec 07, 2017: Cassiopea Announces Completion of Recruitment of Phase II Proof of Concept Trial of CB-06-02 Trial in Genital Warts

Sep 06, 2017: RXi Pharmaceuticals Announces Completion of Enrollment of Phase 2 Clinical Trial with Samcyprone for Cutaneous Warts

Jun 29, 2017: Aclaris Therapeutics Initiates Phase 2b Clinical Trials of A-101 for Topical Treatment of Common Warts

Apr 26, 2017: Aclaris Therapeutics Announces Notice of Allowance for a U.S. Patent Application Covering Lead Candidate A-101 Topical Solution

Mar 02, 2017: Novan's Phase 2 Results with SB206 to be Presented at 2017 AAD Annual Meeting

Mar 01, 2017: Novan Announces Presentation of Anti-Viral Data at International Papillomavirus Conference

Nov 29, 2016: Novan Announces Statistically Significant Phase 2 Clinical Trial Results for SB206

Aug 18, 2016: Aclaris Therapeutics Announces Positive Results in Phase 2 Clinical Trial of A-101 for Treatment of Common Warts

Jul 30, 2016: Cytovation granted EU patent for its lead product, CyPep-1, for the treatment of cutaneous warts

Jul 21, 2016: RXi Pharmaceuticals to Present at the 2016 Summer Meeting of the American Academy of Dermatology

May 10, 2016: Novan to Present Anti-viral Data for Nitric Oxide Product Candidate SB206

Dec 21, 2015: RXi Pharmaceuticals Announces the Initiation of a Phase 2 Trial in Dermatology with Samcyprone for Cutaneous Warts

Dec 07, 2015: Aclaris Therapeutics Initiates Phase 2 Clinical Trial of A-101 for Treatment of Common Warts

May 13, 2015: VCRO Announces Phase II IND Package in Common Technical Document (CTD) Accepted by the USA FDA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Warts, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Warts - Pipeline by Aclaris Therapeutics Inc, H1

Warts - Pipeline by Agilvax Inc, H1

Warts - Pipeline by Aviragen Therapeutics Inc, H1

Warts - Pipeline by BioMAS Ltd, H1

Warts - Pipeline by Cadila Healthcare Ltd, H1

Warts - Pipeline by Cutanea Life Sciences Inc, H1

Warts - Pipeline by Cytovation AS, H1

Warts - Pipeline by G&E Herbal Biotechnology Co Ltd, H1

Warts - Pipeline by Genetic Immunity Inc, H1

Warts - Pipeline by Laboratories Ojer Pharma SL, H1

Warts - Pipeline by LEO Pharma A/S, H1

Warts - Pipeline by Nielsen Biosciences Inc, H1

Warts - Pipeline by Novan Inc, H1

Warts - Pipeline by Novartis AG, H1

Warts - Pipeline by Promius Pharma LLC, H1

Warts - Pipeline by RXi Pharmaceuticals Corp, H1

Warts - Pipeline by Tamir Biotechnology Inc, H1

Warts - Dormant Projects, H1

Warts - Discontinued Products, H1

List of Figures

Number of Products under Development for Warts, H1

Number of Products under Development by Companies, H1

Number of Products by Top 10 Targets, H1

Number of Products by Stage and Top 10 Targets, H1

Number of Products by Top 10 Mechanism of Actions, H1

Number of Products by Stage and Top 10 Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Top 10 Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Aclaris Therapeutics Inc
  • Agilvax Inc
  • Aviragen Therapeutics Inc
  • BioMAS Ltd
  • Cadila Healthcare Ltd
  • Cutanea Life Sciences Inc
  • Cytovation AS
  • G&E Herbal Biotechnology Co Ltd
  • Genetic Immunity Inc
  • Laboratories Ojer Pharma SL
  • LEO Pharma A/S
  • Nielsen Biosciences Inc
  • Novan Inc
  • Novartis AG
  • Promius Pharma LLC
  • RXi Pharmaceuticals Corp
  • Tamir Biotechnology Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll